^
    Back
    Association details:
    Biomarker:TPBG expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:PF-06263507 (Microtubule inhibitor, 5T4-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Haematologica
    Title:

    Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia

    Excerpt:
    While dexamethasone or A1mcMMAF alone improved outcomes, the sequential administration of dexamethasone and A1mcMMAF significantly improved survival (P=0.0006) over either monotherapy. These data show that specifically targeting minimal residual disease cells improved outcomes and support further investigation of A1mcMMAF in patients with high-risk B-cell precursor acute lymphoblastic leukemia identified by 5T4 expression at diagnosis.
    Secondary therapy:
    dexamethasone
    DOI:
    10.3324/haematol.2016.158485